About Cipla Pharma and Life Sciences Limited
Data last updated:
Cipla Pharma and Life Sciences Limited is a public limited company based in Mumbai, Maharashtra, India, a subsidiary of Cipla Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 20 August 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH2008PLC381559. Its GSTIN is 30AADCB5418M1ZU (Goa).
The company has an authorised share capital of ₹275 Cr and a paid-up capital of ₹258.71 Cr. It was formerly known as Biomab Pharmaceuticals (India) Private Limited and Cipla Biotec Private Limited. It is led by directors including Sunil Jvalaprsad Gupta (Managing Director) and Jinesh Chauhan (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Tower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,598.45 Cr, a decline of 2% compared to the previous year. For the same year it recorded a net profit of ₹332.32 Cr (net margin 20.8%) and EBITDA of ₹471.14 Cr (EBITDA margin 29.5%). Revenue has grown at a compounded annual rate (CAGR) of 336% over three years.
The company has about 204 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Cipla Biotec. Court records list 4 cases involving the company, including 3 filed by the company and 1 filed against it; 2 cases are pending. The company has 7 deals on record (5 funding rounds, 2 secondary share transfers), with disclosed funding of ₹426.75 Cr; the latest was in July 2016. Its 3 peer companies in the Pharma industry (Contract Research, Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 2 smaller; the largest is Palepu Pharma Distributors Private Limited with revenue of ₹1,608.11 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ciplabiotec.com.
Company details
Name history
Cipla Pharma and Life Sciences has undergone 3 name changes throughout its history. The company was previously known as Biomab Pharmaceuticals (India) Private Limited, Cipla Biotec Private Limited, and Mabpharm Private Limited. The current legal name is Cipla Pharma And Life Sciences Limited.
| Company Name | Status |
|---|---|
| Cipla Pharma and Life Sciences Limited | Current |
| Biomab Pharmaceuticals (India) Private Limited | Previous |
| Cipla Biotec Private Limited | Previous |
| Mabpharm Private Limited | Previous |
CIN history
Cipla Pharma and Life Sciences has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239MH2008PLC381559, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH2008PLC381559 | Current |
| U24239GA2008PLC007374 | Previous |
| U24239MH2008PTC185974 | Previous |
| U24239GA2008PTC007374 | Previous |
Contact details
Cipla Pharma and Life Sciences Limited's registered office is in Mumbai, Maharashtra. Its website is ciplabiotec.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressTower A 1st Floor Peninsula Business Park Ganpatrao Kadam Marg Lower Parel, Mumbai, Maharashtra, India – 400013
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Cipla Pharma and Life Sciences Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Cipla Pharma and Life Sciences operates one associated brand: Cipla Biotec. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Monoclonal antibodies (mAb) to treat cancers & Wet Age-Related Macular Degeneration and Peptide hormone to treat diabetes. | ciplabiotec.com |
Business activity
The main business activity of Cipla Pharma and Life Sciences is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Cipla Pharma and Life Sciences Limited, buy the company report.
Financials of Cipla Pharma and Life Sciences Limited
FY 2025 filings availableCipla Pharma and Life Sciences Limited reported revenue of ₹1,598.45 Cr (down 2% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 2% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 336%. EBITDA fell 13% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹471.14 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹332.32 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 29.5% | ||||
| Net Profit Margin | 20.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cipla Pharma and Life Sciences Limited, buy the company report.
Board of directors of Cipla Pharma and Life Sciences Limited
Cipla Pharma and Life Sciences has 5 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Anisha Naresh Udeshi | Director | 08 Jun 2020 | 6 Years 5 Months | Current |
| Sunil Jvalaprsad Gupta Also directs: Inzpera Healthsciences Limited | Managing Director | 02 Feb 2024 | 2 Years 9 Months | Current |
| Jinesh Chauhan | Whole-Time Director | 01 Apr 2023 | 3 Years 7 Months | Current |
| Rajendra Kumar Chopra Also directs: Meditab Specialities Limited, Goldencross Pharma Limited, Cipla Pharmaceuticals Limited and 3 more | Director | 02 Jan 2019 | 7 Years 10 Months | Current |
| Raju Sunil Mistry | Additional Director | 01 Jun 2025 | 1 Years 5 Months | Current |
Peer comparison
Cipla Pharma and Life Sciences Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research, Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Palepu Pharma Distributors Private Limited | ₹1,608.11 Cr (FY 2025) | 15.0% | Chennai, Tamil Nadu, India | |||
| Cipla Pharma and Life Sciences Limitedthis company | ₹1,598.45 Cr (FY 2025) | ₹332.32 Cr | 20.8% | -2.0% | 204 | Mumbai, Maharashtra, India |
| Neelkanth Pharma Logistics Private Limited | ₹1,531.92 Cr (FY 2025) | 34.0% | Delhi, India | |||
| K.P.Manish Global Ingredients Private Limited | ₹1,395.22 Cr (FY 2025) | 11.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Cipla Pharma and Life Sciences Limited, buy the company report.
Auditor
Cipla Pharma and Life Sciences Limited is audited by Walker Chandiok & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2023 | 001076N/N500013 |
Shareholding
The shareholding of Cipla Pharma and Life Sciences Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Cipla Pharma and Life Sciences Limited, buy the company report.
Deals & funding
Cipla Pharma and Life Sciences Limited has 7 deals on record (5 funding rounds, 2 secondary share transfers), with disclosed funding of ₹426.75 Cr; the latest was in July 2016.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2016 | Funding round | ₹171.66 Cr | Investors: Cipla Limited |
| Sep 2014 | Funding round | ₹152.21 Cr | Investors: Cipla Limited |
| Jul 2014 | Secondary share transfer | Undisclosed | Buyer: Cipla Limited Seller: Mabpharm Singapore Private Limited |
| Oct 2012 | Funding round | ₹51.74 Cr | Investors: Cipla Limited |
| Aug 2010 | Funding round | ₹16.73 Cr | Investors: Mabpharm Singapore Private Limited |
To see the full deal history of Cipla Pharma and Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cipla Pharma and Life Sciences Limited has 4 court cases on record: 3 filed by Cipla Pharma and Life Sciences, 1 filed against it. 2 cases are pending and 2 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 0 | 1 |
| High courts | 1 | 0 | 0 |
| Supreme Court | 1 | 1 | 1 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case | Filed against the company by Deputy Commissioner of Income Tax | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMARY CASE) | Filed by the company against an individual | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed by the company against Akash Goyal Proprietor of M/S Deepak Medical Agency | Disposed |
| High Court, MAHARASHTRA | Writ petition | Filed by the company against Deputy Commissioner of Income Tax Circle 1 ( and 4 others | Disposed |
To see the full case history of Cipla Pharma and Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Cipla Pharma and Life Sciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Cipla Pharma and Life Sciences Limited has a workforce of 204 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 204 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Cipla Pharma and Life Sciences Limited, buy the company report.
GST
Cipla Pharma and Life Sciences has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 30AADCB5418M1ZU | Goa | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Cipla Pharma and Life Sciences Limited, buy the company report.
Recent activity
Cipla Pharma and Life Sciences Limited has 22 board changes on record since 2011: 5 appointments and 17 cessations. The latest: Raju Sunil Mistry ceased to be Additional Director on 29 Sep 2025.
13 earlier events are in the company report.
News
Frequently asked questions
Cipla Pharma and Life Sciences is an active public limited company based in Mumbai, Maharashtra, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 20 August 2008 (18+ years old) and is registered under CIN U24239MH2008PLC381559.
Cipla Pharma and Life Sciences has 5 current directors:
- Sunil Jvalaprsad Gupta - Managing Director
- Jinesh Chauhan - Whole-Time Director
- Anisha Naresh Udeshi - Director
- Rajendra Kumar Chopra - Director
- Raju Sunil Mistry - Additional Director
The latest financial statements of Cipla Pharma and Life Sciences on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Cipla Pharma and Life Sciences is 30AADCB5418M1ZU, registered in Goa.
The CIN (Corporate Identification Number) of Cipla Pharma and Life Sciences is U24239MH2008PLC381559. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cipla Pharma and Life Sciences has 4 court cases on record: 3 filed by the company and 1 filed against it. 2 are pending. Most are in the district courts.
Cipla Pharma and Life Sciences was incorporated on 20 August 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.
Cipla Pharma and Life Sciences has 7 deals on record (5 funding rounds, 2 secondary share transfers), with disclosed funding of ₹426.75 Cr; the latest was in July 2016.
The peers of Cipla Pharma and Life Sciences by revenue are Palepu Pharma Distributors Private Limited, Neelkanth Pharma Logistics Private Limited, K.P.Manish Global Ingredients Private Limited, all in the Pharma industry (Contract Research, Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Raju Sunil Mistry ceased to be Additional Director on 29 Sep 2025. Raju Sunil Mistry was appointed as Additional Director on 01 Jun 2025. Sunil Jvalaprsad Gupta ceased to be Additional Director on 11 Mar 2024. Cipla Pharma and Life Sciences has 22 board changes on record in total.
Cipla Pharma and Life Sciences can be reached through the website ciplabiotec.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
